Approximately 1,600 patients around the world will take part in the endurance and expedition trials of a combination of pharmaceutical company AbbVie's investigative therapies ABT-493 and ABT-530, which will help to determine if the drugs can be used as a treatment for chronic hepatitis C (HCV) infections.
Six global studies will take place during this phase. The therapies are both oral treatments. ABT-493 is a ribavirin-free investigational drug; ABT-530 is a NS3/4A protease inhibitor.
"We believe AbbVie's work in hepatitis C has contributed to the transformation of HCV care over the last few years," Dr. Michael Severino, chief scientific officer of AbbVie, said. "Our journey continues with the initiation of these Phase III studies, which we hope will help us meet the needs of an even broader range of patients living with hepatitis C."
Patients in this phase of the study will be evaluated 12 weeks after treatment. The studies will use placebo and treatment-naïve patients; patients in all stages of disease will be eligible for the study.
For more information about the clinical trials or to inquire about enrolling, visit www.clinicaltrials.gov.
